UCL DEPARTMENT OF BIOCHEMICAL ENGINEERING

Biochemical Engineering

• Homepage
• About the Department
• Information for prospective students
• Information for industry
  • MBI® Training
    • MBI® courses
      • MBI® course booking
    • MBI® e-learning
    • News
    • MBI® gallery
  • BiCE
  • IMRC
  • RegenMed
  • EngD collaborations
  • Work with us
  • Bioprocessing Matters
  • VISION executive training
  • EPSRC Centre
• Information for teachers
• Information for alumni
• Recent News
• Intranet

Cell Therapy Bioprocessing

Learn how to achieve consistency and high efficiency

20 - 22 February 2012

Achieving consistency and high efficiency is critical when using stem cells for regenerative medicine or drug evaluation and this is true for both discovery and development studies. To achieve it there is a need to understand the effect of the whole bioprocess sequence from cell sourcing and isolation, through expansion, differentiation and implantation into the patient. Through a series of lectures and problem solving case studies stem cells (embryonic, fetal and adult), adult cells and tissue-engineered constructs, will be discussed.

"Inspirational talks and excellent in-depth discussions with presenters" - Muna Whyte, Smith & Nephew

"I really enjoyed the presentations on the automation of tissue culture procedures. I've always heard about the potential of this, but was amazed by the videos that were shown." - Cathy Oliveira, ReNeuron

Previous companies attending have included Avecia, Biosynergy, Capsant, CELS, GE Healthcare AB, InterMark, Johnson & Johnson, MRC, NovaThera, Odontis, Plasticell, Proval Technologies, ReNeuron, Sanofi-Aventis, Smith & Nephew, TEOX and Wyeth.

Who should attend?

Stakeholders in the cell-based therapy sector who plan or are progressing a cell or tissue-engineered therapy through translation and into routine clinical practice.  The course comprehensively covers both the service (autologous) and universal (allogenic) approach to whole bioprocessing.

Programme

Stem Cells; Sourcing, Characterisation and Banking

• Deriving a human embryonic stem cell line
• UK Stem Cell Bank

Stem Cell Expansion

• Automation of human embryonic stem cell expansion and differentiation
• Contract manufacture and stem cells

Cell Therapies

• Embryonic cells
• Fetal and adult stem cells
• Adult cells

Tissue Engineering

• Tissue engineering in a commercial environment - allogeneic therapies
• Challenges of autologous tissue engineering

Case Studies: Adult Stem Cell Therapy and Engineered-Tissue Therapy

• Defining the bioprocess from cell sourcing to patient implantation
• Meeting regulatory and economic challenges
• Allogeneic versus autologous approaches

Module Leaders: Chris Mason, UCL and Farlan Veraitch, UCL

Previous Expert Speakers include: Chris Bravery, MHRA; Julian Burke, Genetix Group plc; Julie Daniels, Moorfields Eye Hospital NHS Foundation Trust; Rosemary Drake, The Automation Partnership Ltd; Andrew Hope, ReNeuron plc; Charles Hunt, UK Stem Cell Bank, NIBSC; Penny Johnson, Intercytex; Bo Kara, Avecia plc; Paul Kemp, Intercytex; Sheila MacNeil, CellTran Ltd; Sakis Mantalaris, NovaThera Ltd; Nick Medcalf, Smith & Nephew plc; Mike Scott, Addenbrooke’s Hospital; Glyn Stacey, UK Stem Cell Bank, NIBSC; Hazel Thomson, Stem Cell
Sciences plc; Mike Watts, UCLH

A networking dinner will be held on the first evening.

The module costs £1300, with a £100 discount if you register and pay before 12 February.

Download the Flyer

Book now!

---